Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck
This study aimed to assess the efficacy and safety for biweekly TPF as induction chemotherapy for locally advanced head and neck cancer
Locally Advanced Head and Neck Carcinoma
DRUG: docetaxel, cisplatin, fluorouracil
Response rate after induction chemotherapy, CT and PET scan according to the RECIST 1.1 criteria., through study completion, an average of 1 years
Progression survival, The time from the study registration date to the first day of disease progression at any site, Through study completion, an average of 6 months|Overall survival, The time from the study registration date to the day of the patients' death., Through study completion, an average of 6 months|Adverse event, Record adverse event, through study completion, an average of 6 months
After being informed the study and potential risk, patients was provided written informed consent prior to initiating therapy. The chemotherapy regimen including docetaxel, cisplatin, 5-fluorouracil, and leucovorin was administered every 14 days for six cycles or until disease progression or intolerant treatment toxicity.